Case reports describing the use of bisphosphonates resulting in symptomatic and scintigraphic improvement of melorheostosis have also been published.22 Given accelerated bone remodeling in affected bone of patients with MAP2K1‐positive melorheostosis, it is biologically appealing to postulate a role for antiresorptives. This evidence concerns the gene MAP2K1 and melorheostosis.